TESTOSTERONE THERAPY
Clomid / Enclomiphene
Oral hormone-signaling medication that may support endogenous testosterone production while preserving testicular function in selected men.
What it is
Clomiphene and enclomiphene are selective estrogen receptor modulators used off-label in some men with secondary testosterone deficiency. Rather than supplying testosterone directly, they influence pituitary hormone signaling.
How it works
By changing estrogen feedback at the brain, these medicines can increase luteinizing hormone and follicle-stimulating hormone signals. The testes may then produce more testosterone and sperm. A clinician uses symptoms, testosterone levels, estradiol, and fertility goals to guide treatment.
Who it is for
- Men with secondary low testosterone under physician evaluation
- Men who wish to preserve fertility potential
- Men who prefer an oral approach over testosterone replacement
Mechanism in depth
Clomiphene and its purer isomer enclomiphene are selective estrogen receptor modulators. They bind estrogen receptors in the hypothalamus and pituitary and block negative feedback from circulating estradiol. That releases the brakes on luteinizing hormone and follicle-stimulating hormone signals to the testes, which respond by producing more testosterone and sperm. Unlike exogenous testosterone, this pathway does not suppress the HPG axis and generally preserves fertility.
What outcomes to expect
Blood testosterone typically begins to rise within two to four weeks. Many patients experience improved energy, libido, and mood over six to twelve weeks. Fertility markers such as sperm concentration may take three to six months to reflect changes. Response varies — men with primary testicular failure will not respond, which is why baseline LH, FSH, and testosterone testing matter.
Individual response varies. GPLX does not guarantee results. Your physician sets expectations based on your health history and lab findings.
Common side effects
Reported side effects include mood shifts, visual disturbances at higher doses, mild breast tenderness, headache, and gastrointestinal upset. Estradiol can rise, which sometimes requires dose adjustment. Rare but serious concerns include visual changes that persist after stopping the drug.
Monitoring schedule
GPLX typically reviews labs at four to six weeks after starting therapy, including total testosterone, estradiol, LH, and FSH. Ongoing monitoring occurs every three to six months, plus symptom check-ins. Fertility-focused patients may add semen analysis at intervals guided by your physician.
Not appropriate if
Not appropriate if you have primary testicular failure, active liver disease, an active retinal or visual disorder, hormone-sensitive tumors, or if pregnancy is possible. Your physician reviews your full history and prior fertility data before prescribing.
Biomarkers reviewed with this treatment
Your physician reviews these markers before and during therapy. Click any marker for a plain-English explanation of what it measures and why it matters.
This treatment is only available after a physician consultation. Book your $149 intake to see if it is appropriate for you.
Book a $149 Consultation